Ignite Creation Date:
2024-10-26 @ 3:40 PM
Last Modification Date:
2024-10-26 @ 3:40 PM
Study NCT ID:
NCT06599307
Status:
RECRUITING
Last Update Posted:
None
First Post:
2024-09-10
Brief Title:
The Effect of Rituximab on Cognitive and Hand Functions in Secondary Progressive Multiple Sclerosis
Sponsor:
None
Organization:
None
Study Overview
Official Title:
The Effect of Rituximab on Cognitive and Hand Functions in Secondary Progressive Multiple Sclerosis a Randomized Controlled Trial
Status:
RECRUITING
Status Verified Date:
2024-09
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
No
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
None
Brief Summary:
The goal of this clinical trial is to know if rituximab can improve cognitive and hand functions in secondary progressive multiple sclerosis SPMS patients with high disability EDSS 65 or more The main questions it aims to answer are
Can rituximab improve cognitive and hand functions in SPMS patients Can rituximab improve the quality of life and the Expanded Disability Status Scale EDSS in SPMS patients
Researchers will compare patients who receive rituximab to patient who receive placebo to see the effects of rituximab on cognition hand functions quality of life and EDSS
Demographic and clinical data as age gender disease duration and EDSS will be obtained from each participant Participants will perform The Brief International Cognitive Assessment for Multiple Sclerosis BICAMS The Nine-Hole Peg Test 9-HPT and The MS-QLQ27 questionnaire at baseline and after one year of receiving either rituximab or placebo
Can rituximab improve cognitive and hand functions in SPMS patients Can rituximab improve the quality of life and the Expanded Disability Status Scale EDSS in SPMS patients
Researchers will compare patients who receive rituximab to patient who receive placebo to see the effects of rituximab on cognition hand functions quality of life and EDSS
Demographic and clinical data as age gender disease duration and EDSS will be obtained from each participant Participants will perform The Brief International Cognitive Assessment for Multiple Sclerosis BICAMS The Nine-Hole Peg Test 9-HPT and The MS-QLQ27 questionnaire at baseline and after one year of receiving either rituximab or placebo
Detailed Description:
None
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
None
Is a FDA Regulated Device?:
None
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None